CLEO receives first commercial test kits, triggering start of Analytical Validation
Ovarian cancer diagnostics company Cleo Diagnostics Limited (ASX:COV) has received the first production batch of commercially manufactured test kits from Bio-Techne (NASDAQ:TECH), clearing the way for Analytical Validation of its Pre-Surgical Ovarian Cancer Test to commence.
The delivery marks a significant milestone in the Company’s regulatory program. It progresses the test toward CLEO’s planned FDA 510(k) submission in H1 CY2027.
CLEO received 125 test kits as part of the first batch. These will now undergo standard internal quality control and documentation procedures ahead of formal commencement of Analytical Validation, a process the Company expects to take 1-2 weeks.
The arrival of batch 1 follows completion of assay development and optimisation activities required to translate CLEO’s technology into its commercial test format. For investors, this represents the transition from development into the formal validation phase that generates regulatory evidence, a clear value inflection point on the path to submission.
When big ASX news breaks, our subscribers know first
Inside the three-batch Analytical Validation program
CLEO’s Analytical Validation program will evaluate three independently manufactured production batches of commercial test kits produced by U.S.-based Bio-Techne. The structure is designed to establish the analytical performance of CLEO’s eight-biomarker assay and demonstrate that this performance can be reproduced consistently across separate manufacturing runs.
Testing of the first production batch will establish the core analytical performance characteristics and validated operating parameters for each of the eight biomarkers. This provides the foundational reference dataset against which subsequent independently manufactured batches will be evaluated.
The second and third batches will then be used to demonstrate that the analytical performance established through the first batch is reproducible across independent manufacturing runs and is not dependent on an individual production lot.
Evaluated together, the three-batch approach is designed to demonstrate four key objectives:
- Precision of the assay across measurements
- Reproducibility across independent manufacturing runs
- Manufacturing consistency between production lots
- Analytical robustness of the commercial test
CLEO currently anticipates receiving the second and third production batches from Bio-Techne during Q4 CY2026, with testing to occur as part of the ongoing program. The Company is targeting completion of Analytical Validation by the end of CY2026. This staged evaluation is intended to de-risk manufacturing scale-up while strengthening the regulatory evidence base ahead of FDA submission.
Why Analytical Validation matters, a beginner’s guide
Analytical Validation is the process of confirming that a diagnostic test performs reliably and reproducibly from an analytical standpoint before it is applied to patients. It measures whether the test delivers accurate, consistent and robust results, independent of which manufacturing batch is used.
This differs from the subsequent Clinical Validation phase. Clinical Validation measures how the test performs in the real world, within the intended patient population, rather than under controlled analytical conditions.
The sequencing matters to investors. Analytical Validation generates what the Company describes as a critical component of the regulatory evidence required to support its planned FDA 510(k) submission. Without it, the program cannot progress into clinical testing.
The underlying opportunity is substantial. Ovarian cancer has the highest five-year mortality rate of all cancers affecting women, with 51% of patients dying within five years, driven largely by late diagnosis and the lack of effective screening tools. CLEO’s test targets this unmet clinical need. Its patented technology is based on the CXCL10 biomarker, supported by over 15 years of scientific research and development.
The remaining pathway to FDA submission
CLEO has set out a defined roadmap from its current position at Analytical Validation through to FDA submission. Following successful completion of validation and finalisation of the commercial assay algorithm, the Company will progress into Clinical Validation, which will evaluate the test’s clinical performance in its intended patient population.
Clinical Validation will include analysis of the prospective blood samples already collected through CLEO’s pivotal U.S. clinical trial, together with samples from healthy individuals and patients presenting with relevant confounding conditions. Having these samples collected reduces timeline risk heading into this phase.
The pivotal U.S. clinical trial enrolled 624 women across 19 sites and secured 514 usable blood samples, surpassing the minimum recruitment threshold and removing a key timeline risk that would otherwise have extended the path to FDA submission.
Preparations are well underway, with the Company in final negotiations with a CLIA-certified laboratory to conduct the clinical testing program.
The remaining major milestones prior to FDA submission are:
- Analytical Validation (including testing of three production batches)
- Finalisation of commercial assay algorithm
- Clinical Validation (including testing of pivotal clinical trial and control samples)
- Clinical data analysis and trial results
- FDA 510(k) submission
| Milestone | Status / Phase | Expected Timing |
|---|---|---|
| Manufacturing of commercial test kits (Batch 1) | Complete | Delivered |
| Analytical Validation | In progress — WE ARE HERE | Q3 CY2026 – Q4 CY2026 |
| AV completion | Targeted | End CY2026 |
| Clinical Validation | Upcoming | Q1 CY2027 – Q2 CY2027 |
| FDA 510(k) submission | Planned | H1 CY2027 |
With a clearly defined, sequential pathway and clinical samples already collected, investors gain visibility on a series of catalysts running through 2027.
Management view
Dr Richard Allman, Chief Executive Officer of CLEO, framed the milestone as the start of an execution-focused period for the Company.
Dr Richard Allman, Chief Executive Officer
“From here, the pathway is clearly defined. We will conduct AV across the three manufactured batches before progressing into CV, where we will generate the pivotal clinical performance data for our test.
With our prospective clinical samples already collected and the first commercial test kits now undergoing validation, we are entering an important period of execution for CLEO as we progress towards clinical results, FDA submission and ultimately commercialisation.”
Allman also noted that receipt of the first batch “represents the culmination of significant work undertaken to translate CLEO’s technology into a reproducible commercial assay.”
What it means for investors
The delivery of the first commercial test kits moves CLEO from development into the formal regulatory validation phase, the stage that produces FDA-grade evidence. Each validated batch and completed phase incrementally de-risks the path to a diagnostic addressing a major unmet clinical need in ovarian cancer.
The defined pathway also gives investors near-term catalyst visibility. Analytical Validation is targeted for completion by the end of CY2026, Clinical Validation is expected across Q1–Q2 CY2027, and the FDA 510(k) submission remains targeted for H1 CY2027.
With prospective clinical samples already collected and validation now underway, the coming quarters are set to test whether CLEO can convert its regulatory roadmap into the evidence base required to advance toward submission and commercialisation.
Don’t Miss the Next Healthcare Breakthrough on ASX
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive alerts the moment market-moving announcements hit the ASX.